The global biopharmaceutical CMO & CRO (contract manufacturing &research) market is expected to reach USD 37.8 billion
by 2025, according to a new report by Grand View Research, Inc. Healthy outlook
of biopharmaceuticals and consequent growth in biopharmaceutical pipelines has
resulted into lack of adequate capacity and budget constraints. These factors
have convinced many traditional drug developers to take advantage of
cost-saving benefits associated with contract services. Traditional biopharmaceutical
players are observed to choose outsourcing biopharmaceutical manufacturing
rather than making an investment of expensive capital in production equipment
and hiring skilled labor.
Significant improvement in the services
offered by this CMOs/CROs in context to maturity of complex technology is
spurring the adoption of these services. In addition, wide acceptance of
single-use technology within CMOs/CROs has significantly transformed the
CMOs/CROs landscape by enhancing their capabilities and enabling them to
develop products at low operating costs.
Outsourcing services are observed to play
critical role in overcoming trade barriers for firms. It enables them to make
footprints in foreign market where government regulates to secure local employment
through domestic production. Furthermore, as a result of growing demand for
these services, smaller companies have also begun to expand their non-GMP
facilities.
Browse full report by Grand View
Research : http://www.grandviewresearch.com/industry-analysis/biopharmaceutical-cmo-cro-market
Further key findings from the report suggest:
·
Mammalian cell line-based bioproduction
system dominated the share in 2016 in terms of revenue generation
·
This can be attributed to the presence of
substantial number of mammalian-based manufacturing platforms offered by market
leaders such as Lonza, Samsung BioLogics, WuXi Biologics
·
CMOs are providing wide range of services
for entire chain of biopharmaceutical manufacturing process, consequently held
the largest share
·
Growing R&D investment in bioproduction
is the high impact rendering factor for the growth of CROs
·
Robust biologics pipeline and high
production cost of biologics have contributed to the largest share of biologics
outsourcing
·
Monoclonal antibodies accounted for
significant share in 2016 owing to the huge success rate of MAbs for disease
treatment
·
North America is home to large number of
biopharmaceutical manufacturing entities, which in turn, have resulted into
large share of this region
·
Being a lower wage country, China and India
are expected to be fastest growing regional market
·
Several global companies are translocating
their business to Asia Pacific owing to low manufacturing costs in Asian
countries
·
Boehringer Ingelheim GmbH, Lonza, Samsung
BioLogics, Patheon, FUJIFILM Diosynth Biotechnologies U.S.A., Inc. are some of
the major companies operating in this space
Browse more reports of this category by Grand View
Research: https://www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented the
global biopharmaceutical CMO & CRO market on the basis of source, service,
product, and region:
Source Outlook (Revenue, USD Million, 2014 - 2025)
·
Mammalian
·
Non-mammalian
Service Outlook (Revenue, USD Million, 2014 - 2025)
·
Contract Manufacturing
o Process Development
o Downstream
o Upstream
o Fill & Finish Operations
o Analytical & QC studies
o Packaging
·
Contract Research
o Oncology
o Inflammation & Immunology
o Cardiology
o Neuroscience
o Others
Product Outlook (Revenue, USD Million, 2014 - 2025)
·
Biologics
o Monoclonal antibodies (MAbs)
o Recombinant Proteins
o Vaccines
o Antisense, RNAi, & Molecular Therapy
o Others
·
Biosimilars
Regional Outlook (Revenue, USD Million, 2014 - 2025)
·
North America
o U.S.
o Canada
·
Europe
o Germany
o France
·
Asia Pacific
o China
o Japan
·
Latin America
o Brazil
·
Middle East & Africa
o South Africa
View Press Release of this research report by Grand View
Research: https://www.grandviewresearch.com/press-release/global-biopharmaceutical-cmo-cro-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For More Information: www.grandviewresearch.com
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For More Information: www.grandviewresearch.com
